At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 413 enrolled
Drug / intervention
BOL-303259-X +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Single-Masked, Parallel-Group Dose Finding Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Open Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 2 clinical trial evaluating BOL-303259-X and Latanoprost for Intraocular Pressure. Completed, enrolled 413 participants across 1 site.
Detailed Summary
The objective of this clinical investigation is to determine the most effective drug concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical development of an appropriate dose with regard to efficacy, and ocular and systemic safety.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntraocular Pressure
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartDec 2010
Primary CompletionDec 2011
Study CompletionJun 2012
TodayJul 2026
First PostedOct 19, 2010
Enrollment StartDec 13, 2010
Primary CompletionDec 20, 2011
Study CompletionJun 22, 2012
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 15.7 years ago
Interventions
BOL-303259-Xdrug
ophthalmic solution, various concentrations, once daily (QD) 28 days
Latanoprostdrug
0.005% ophthalmic solution, QD 28 days